New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumors
A Ludwig Cancer Research study shows that ovarian cancer, which has proved resistant to currently available immunotherapies, could be susceptible to personalized immunotherapy. Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells—which kill infected and cancerous cells—and demonstrates how they can be identified and selectively grown for use in personalized, cell-based immunotherapies.
“Tumors whose cells tend to be highly mutated, like those of melanoma and lung cancer, are the ones that respond best to immunotherapies,” says Harari. “It has long been a question whether we’d even be able to detect sufficiently mutation-reactive T cells in patients with tumors that have low mutational loads.”
Harari, Coukos and their colleagues report in Nature Communicationsthat, despite their low mutational load, epithelial ovarian tumors are infiltrated with T cells that are especially good at recognizing and killing cancer cells.
Cancer cells that have a relatively large number of mutations in their DNA express aberrant proteins—or neoantigens—that reveal the cancer to the immune system. Killer T cells recognize tiny, mutated bits of these antigens, known as neoepitopes. But neoepitopes vary wildly from patient to patient, even within the same type of cancer. This has long stymied efforts to develop generally effective therapies that target cancer antigens.
To get around this problem, researchers have been developing sophisticated methods to extract T cells from patients, select and expand those that best target a patient’s cancer and reinfuse them into the patient. These approaches usually rely on T cells extracted from the bloodstream, not those already inside the tumor, which are referred to as TILs (for tumor infiltrating lymphocytes).
Experimental therapies using T cells taken from the blood stream have not, however, worked very well against solid tumors. Further, when TILs have been used for such purposes, the proportion of what Harari calls the “juiciest” T cells—those recognizing mutations on cancer cells—tends to decline significantly when the cells are expanded in culture.
“To circumvent these problems, we developed a new methodology to identify highly reactive TILs and expand them in a manner that, rather than diluting the juiciest TILs, enriches them instead,” says Harari. “This allowed us to compare the activity of TILs that target neoepitopes with their counterparts in the peripheral bloodstream.”
The researchers show that killer T cells isolated from ovarian tumors using their method are much better at both recognizing neoepitopes than are those isolated from blood.
“We could even compare T cells from the two compartments targeting the exact same mutation and show that the TILs were more functional than the T cells we collected from the peripheral bloodstream,” says Harari.
Notably, the researchers found that, using their methods, highly reactive TILs could be obtained from some 90% of the ovarian cancer patients whose tumor samples they examined.
“The big message,” says Coukos, “is that future cell-based therapies can be envisioned for low mutational load tumors and should prioritize the use of TILs over T cells collected from peripheral blood. This novel strategy to obtain enriched TILs also offers great therapeutic opportunities.”
Harari, Coukos and their colleagues will now be applying their findings to an ambitious program to develop and streamline personalized immunotherapies for cancer patients currently underway at the Lausanne Branch of the Ludwig Institute for Cancer Research.
The Latest on: Personalized cell-based immunotherapies
via Google News
The Latest on: Personalized cell-based immunotherapies
- Fate Therapeutics: Potential Catalysts Aheadon March 17, 2020 at 11:26 am
Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of next-generation cellular immunotherapies for cancer and immune disorders. The company has pioneered ...
- Cellular Health Assays Marketon March 16, 2020 at 1:01 am
The flexibility to execute a wide variety of protocols within a single system is enabled through a single-use, highly customizable cassette and custom programming. Process development along with ...
- Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigeneon March 10, 2020 at 5:25 pm
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic ...
- Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomeson March 10, 2020 at 3:08 am
Non-canonical HLA-bound peptides from presumed non-coding regions are potential targets for cancer immunotherapy, but their discovery remains challenging. Here, the authors integrate exome sequencing, ...
- MDG1k.D - MediGene AG Profile | Reuterson October 15, 2019 at 5:26 pm
The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments ...
- Medigene - Profileon October 20, 2018 at 4:00 am
It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker ...
- Why Choose UC San Diego Health for Your Cancer Care?on January 26, 2011 at 9:29 am
Moores Cancer Center is one of them — and the only one in the ... These investigational therapies include highly personalized stem cell-based approaches and immunotherapies that leverage the inherent ...
via Bing News